Algorithmic accountability disclosure
Algorithmic accountability disclosure in Healthcare & Life Sciences is no longer a theoretical compliance question. The U.S. Food and Drug Administration's draft guidance on AI/ML-based Software as a Medical Device and the U.S. Federal Trade Commission's enforcement actions under Section 5 of the FTC Act have created overlapping disclosure obligations for health systems and life sciences firms deploying algorithmic decision-support tools. The European Medicines Agency is advancing parallel expectations under the EU AI Act's high-risk classification for medical devices, forcing compliance teams to reconcile transatlantic standards at the contract and vendor level simultaneously.
Watch
- FDA's predetermined change control plan requirements for adaptive AI/ML medical software
- FTC Act Section 5 enforcement pattern targeting opaque clinical algorithm vendors
- EU AI Act Article 13 transparency obligations applied to Class IIa/IIb medical devices
- State-level algorithmic bias disclosure bills pending in California and Illinois targeting health insurers
- ONC HTI-1 rule explainability requirements for certified health IT decision-support interventions
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to algorithmic accountability disclosure will appear here as they are published.